A modified tuberculosis (TB) vaccine developed at Texas Biomed could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects. Results in mouse models and human cells show promising results and pave the way for human clinical trials. The research, conducted in close collaboration with UT Health San Antonio, was published online in June in the journal Cancer Immunology, Immunotherapy.
Researchers at Massachusetts General Hospital (MGH), published a new paper in Cell Reports Medicine demonstrating the protective potential of multiple doses of the Bacillus Calmette-Guerin (BCG) vaccine against COVID-19 and other infectious diseases.
Noninvasive (stage Ta) bladder cancers with “high-grade” characteristics should be considered at high risk of recurrence, concludes a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Being vaccinated during childhood with the BCG (Bacille Calmette-Guérin) vaccine against tuberculosis is not a long-term protective factor against COVID-19, despite what was thought at the beginning of the pandemic.